SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).

Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based...

Descripción completa

Detalles Bibliográficos
Autores: Remon J, Bernabé R, Diz P, Felip E, González-Larriba JL, Lázaro M, Mielgo-Rubio X, Sánchez A, Sullivan I, Massutti B
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p8215
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones8215
Access Level:acceso abierto
Palabra clave:Chemotherapy
Lenvatinib
Multidisciplinary
Nivolumab
Thymic epithelial tumours
id ES_a63bc3d40224b456fefa8a3b52dcaca9
oai_identifier_str oai:isabial.fundanetsuite.com:p8215
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).Remon JBernabé RDiz PFelip EGonzález-Larriba JLLázaro MMielgo-Rubio XSánchez ASullivan IMassutti BChemotherapyLenvatinibMultidisciplinaryNivolumabThymic epithelial tumoursThymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.SPRINGER INT PUBL AG2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones8215Clinical & Translational OncologyISSN: 1699048XISSNe: 16993055reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p82152026-06-12T10:20:37Z
dc.title.none.fl_str_mv SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
title SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
spellingShingle SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
Remon J
Chemotherapy
Lenvatinib
Multidisciplinary
Nivolumab
Thymic epithelial tumours
title_short SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
title_full SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
title_fullStr SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
title_full_unstemmed SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
title_sort SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
dc.creator.none.fl_str_mv Remon J
Bernabé R
Diz P
Felip E
González-Larriba JL
Lázaro M
Mielgo-Rubio X
Sánchez A
Sullivan I
Massutti B
author Remon J
author_facet Remon J
Bernabé R
Diz P
Felip E
González-Larriba JL
Lázaro M
Mielgo-Rubio X
Sánchez A
Sullivan I
Massutti B
author_role author
author2 Bernabé R
Diz P
Felip E
González-Larriba JL
Lázaro M
Mielgo-Rubio X
Sánchez A
Sullivan I
Massutti B
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chemotherapy
Lenvatinib
Multidisciplinary
Nivolumab
Thymic epithelial tumours
topic Chemotherapy
Lenvatinib
Multidisciplinary
Nivolumab
Thymic epithelial tumours
description Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones8215
url https://isabial.portalinvestigacion.com/publicaciones8215
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER INT PUBL AG
publisher.none.fl_str_mv SPRINGER INT PUBL AG
dc.source.none.fl_str_mv Clinical & Translational Oncology
ISSN: 1699048X
ISSNe: 16993055
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415681158545408
score 15,812429

Similares en LA Referencia